NVS लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...

Stats
आज की मात्रा	1.46M
औसत मात्रा	1.63M
बाजार मूल्य	190.64B
EPS	$0 ( 2024-04-23 )
अगली कमाई की तारीख	( $1.850 ) 2024-07-16
Last Dividend	$3.47 ( 2023-03-09 )
Next Dividend	$0 ( N/A )
P/E	22.15
ATR14	$0.0230 (0.02%)

मात्रा सहसंबंध

लंबा: -0.67 (moderate negative)

छोटा: -0.82 (strong negative)

Signal:(23.382) Be Aware. Possible trading coming up! (swing)

Novartis AG सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Novartis AG सहसंबंध - मुद्रा/वस्त्र

-0.50
( neutral )

-0.77
( moderate negative )

0.00
( neutral )

-0.46
( neutral )

-0.29
( neutral )

-0.38
( neutral )

Novartis AG वित्तीय

Annual	2023
राजस्व:	$46.66B
सकल लाभ:	$34.19B (73.27 %)
EPS:	$7.15

FY	2023
राजस्व:	$46.66B
सकल लाभ:	$34.19B (73.27 %)
EPS:	$7.15

FY	2022
राजस्व:	$51.83B
सकल लाभ:	$36.34B (70.12 %)
EPS:	$3.19

FY	2021
राजस्व:	$52.88B
सकल लाभ:	$37.01B (69.99 %)
EPS:	$10.71

Financial Reports:

No articles found.

Novartis AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$3.47 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novartis AG Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.42 - Stable (8.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.966	2000-11-14
Last Dividend	$3.47	2023-03-09
Next Dividend	$0	N/A
Payout Date	2023-03-20
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$44.60	--
Avg. Dividend % Per Year	2.46%	--
Score	4.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.42
Div. Directional Score	7.88	--

Next Divdend (Est)
(2025-01-10)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

4.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	$0.966	2.96%
2001	$0.450	1.12%
2002	$0.468	1.46%
2003	$0.627	1.89%
2004	$0.722	1.57%
2005	$0	0.00%
2006	$0.801	1.50%
2007	$0.969	1.67%
2008	$1.319	2.42%
2009	$1.541	3.11%
2010	$1.780	3.38%
2011	$2.11	3.56%
2012	$2.20	3.78%
2013	$2.27	3.56%
2014	$2.44	3.10%
2015	$2.52	2.73%
2016	$2.47	2.88%
2017	$2.46	3.38%
2018	$2.67	3.15%
2019	$2.57	3.06%
2020	$3.04	3.20%
2021	$3.38	3.58%
2022	$3.36	3.82%
2023	$3.47	3.76%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.307	1.500	3.86	5.79	[0 - 0.5]
returnOnAssetsTTM	0.162	1.200	4.61	5.54	[0 - 0.3]
returnOnEquityTTM	0.346	1.500	7.27	10.00	[0.1 - 1]
payoutRatioTTM	0.342	-1.000	6.58	-6.58	[0 - 1]
currentRatioTTM	0.903	0.800	-0.485	-0.388	[1 - 3]
quickRatioTTM	0.613	0.800	-1.102	-0.881	[0.8 - 2.5]
cashRatioTTM	0.323	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.273	-1.500	5.45	-8.17	[0 - 0.6]
interestCoverageTTM	12.32	1.000	6.55	6.55	[3 - 30]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.96	2.00	7.52	10.00	[0 - 20]
debtEquityRatioTTM	0.649	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.726	1.000	1.237	1.237	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.534	1.000	8.14	8.14	[0.2 - 2]
assetTurnoverTTM	0.526	0.800	9.83	7.86	[0.5 - 2]
Total Score				10.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.346	2.50	8.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.96	2.00	8.35	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
payoutRatioTTM	0.342	1.500	6.58	-6.58	[0 - 1]
pegRatioTTM	-3.02	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.277	1.000	5.57	0	[0.1 - 0.5]
Total Score				5.42

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.